SOT112 / Sotio, Lonza - LARVOL DELTA

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113 (Businesswire) - "SOTIO Biotech...announced it will be exercising its option, under its license and option agreement with Synaffix B.V. ('Synaffix')...to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. The exercised option will enable SOTIO to advance two bispecific candidates, designed by its in-house research team, that have the potential to become first-in-class and/or best-in-class treatments for solid tumors. SOT112 is a bispecific ADC with potential applicability in several major cancer indications, while SOT113 demonstrates promise for precision targeting of prostate cancer. Both programs leverage the selection of highly attractive target pairs and are now in the lead nomination stage. The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix..."

Licensing / partnership • Pipeline update • Prostate Cancer